THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY

Fictional patients used for illustrative purposes.

As an assistant at a marketing company, Rebecca attends several meetings every day and works to tight deadlines.

She needs to stay alert to keep on top of her work, but with her MDD, she struggles to maintain her energy levels and concentration. There are even some days when she finds it hard to get out of bed in the morning.

Depression absence:

Depression is one of the most prevalent health problems in the workplace.² Mental health disorders, including stress, depression, anxiety, and serious mental health conditions accounted for 9.8% of all sickness absence in the UK during 2021.3

Patients like Rebecca receiving Brintellix may see improvements in their attendance at work.4

MDD, major depressive disorder.  

Patients receiving Brintellix are more able to fully engage in their jobs long-term4

The AtWoRC study assessed whether improvements in cognitive symptoms in Brintellix-treated patients correlated with increased work productivity in a real-life setting vs. baseline:4

  • Primary study endpoint was the partial correlation between changes in PDQ-D-20 and WLQ productivity loss scores at Week 12*
  • The percentage of patients reporting missed work days due to depression was significantly reduced from baseline by 52 weeks (secondary outcome)
Proportion of patients with time off work due to depression in the past 3 months (FAS, n=199)
Adapted from: Chokka P et al. 2019.4

*Correlation was assessed by the partial correlation coefficient adjusted for age, sex, baseline PDQ-D-20, baseline WLQ productivity loss, disease duration, and disease severity.

Patients receiving Brintellix see improvements from baseline in their productivity at work4

  • Work productivity loss significantly reduced over the 52-week treatment period vs. baseline (p<0.001)
  • Mean (SD) change from baseline in WLQ productivity loss score was -8.9 (5.9) at 52 weeks
Work productivity loss: mean WLQ score over 52 weeks (FAS, n=199)†
Adapted from: Chokka P et al. 2019.4 *p<0.001. †Functioning and work productivity were assessed by WLQ productivity loss, the SDS, the WPAI questionnaire, and the WHODAS. Changes in WLQ productivity loss over 52 weeks of follow-up are shown; error bars indicate 95% confidence intervals. Statistically significant improvements (p 0.001, paired t test) versus baseline were found at Week 52.

AtWoRC, Assessment in Work productivity and the Relationship with Cognitive symptoms; FAS, Full Analysis Set; PDQ-D-20, 20-item Perceived Deficits Questionnaire – Depression; SD, Standard deviation; SDS, Sheehan Disability Scale; WHODAS 2.0, 12-item World Health Organization Disability Assessment Schedule 2.0; WLQ, Work Limitations Questionnaire; WPAI, Work Productivity and Activity Impairment questionnaire.

Brintellix has demonstrated improvements in patient-reported functioning in real-world patients with MDD5

In the real-world, 24-week observational, prospective cohort study of Brintellix in a large, heterogeneous patient population with MDD (n=737):5

  • Clinically meaningful, sustained improvement in patient functioning was seen over 24 weeks of Brintellix treatment ( p<0.0001)
  • Significant reductions in all SDS domain scores were observed at 12 and 24 weeks vs. baseline (p<0.0001 for both)

  • Depression Severity

  • In the subgroup of patients with moderately severe to severe depression at baseline (PHQ-9 score ≥15), significant and sustained improvements in functioning and all secondary endpoints were seen over the 24 weeks of Brintellix treatment5
  • Mean reductions in absenteeism (work days lost) and presenteeism (work days underproductive) after 24 weeks of Brintellix treatment were 1.1 and 2.2 days/week, respectively5
SDS total and domain scores at baseline and after 12 and 24 weeks (FAS, n=737) (adjusted LS mean (95% CI) score)
Adapted from: Mayyingley GW et al. 2022.5

CI, Confidence interval; FAS, Full analysis set; LS, Least squares; MDD, major depressive disorder SE, standard error; SDS, Sheehan Disability Scale.

For further information about Brintellix, including Tolerability, Special Warnings and Precautions and Contraindications, please visit the About Brintellix Section

about brintellix

Explore more in the sections below:

Adverse events should be reported.

Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Lundbeck Limited, Medical Information, on: 01908 638972 or Email: SafetyLuUnitedKingdom@lundbeck.com

References
  • Lundbeck. Brintellix. Summary of Product Characteristics GB and NI.
  • Sanderson K, Andrews G. Can J Psychiatry. 2006;51:63–75.
  • Office for National Statistics, Sickness absence in the UK labour market: 2021. Available https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/labourproductivity/articles/sicknessabsenceinthelabourmarket/2021. [Last accessed September 2023].
  • Chokka P et al. CNS Spectr 2019;24:616–627.
  • Mattingly GW et al. Front Psychiatry 2022;13:824831.
UK-BRIN-1281 | September 2023

This is a Lundbeck Limited developed and funded website intended for UK healthcare professionals only. This website contains promotional materials.

Please select the link below that is most relevant to you:

UK-BRIN-1539 | February 2024